Slowly Declining Levels of Viral RNA and DNA in DNA/Recombinant Modified Vaccinia Virus Ankara-Vaccinated Macaques with Controlled Simian-Human Immunodeficiency Virus SHIV-89.6P Challenges
Open Access
- 15 October 2002
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (20) , 10147-10154
- https://doi.org/10.1128/jvi.76.20.10147-10154.2002
Abstract
In a recent vaccine trial, we showed efficient control of a virulent simian-human immunodeficiency virus SHIV-89.6P challenge by priming with a Gag-Pol-Env-expressing DNA and boosting with a Gag-Pol-Env- expressing recombinant-modified vaccinia virus Ankara. Here we show that long-term control has been associated with slowly declining levels of viral RNA and DNA. In the vaccinated animals both viral DNA and RNA underwent an initial rapid decay, which was followed by a lower decay rate. Between 12 and 70 weeks postchallenge, the low decay rates have had half-lives of about 20 weeks for viral RNA in plasma and viral DNA in peripheral blood mononuclear cells and lymph nodes. In vaccinated animals the viral DNA has been mostly unintegrated and has appeared to be largely nonfunctional as evidenced by a poor ability to recover infectious virus in cocultivation assays, even after CD8 depletion. In contrast, in control animals, which have died, viral DNA was mostly integrated and a larger proportion appeared to be functional as evidenced by the recovery of infectious virus. Thus, to date, control of the challenge infection has appeared to improve with time, with the decay rates for viral DNA being at the lower end of values reported for patients on highly active antiretroviral therapy.Keywords
This publication has 27 references indexed in Scilit:
- Selective extraction of polyoma DNA from infected mouse cell culturesPublished by Elsevier ,2004
- Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA VaccinesJournal of Virology, 2002
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytesNature, 2002
- Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4 + T CellsJournal of Virology, 2001
- Quantification of Human Immunodeficiency Virus Type 1 Proviral Load by a TaqMan Real-Time PCR AssayJournal of Clinical Microbiology, 2001
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Inhibition of HIV-1 Infection by the β-Chemokine MDCScience, 1997
- Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cellsImmunology Today, 1996
- Inhibition of cellular activation of retroviral replication by CD8+ T cells derived from non-human primatesClinical and Experimental Immunology, 1993